Adverum Biotechnologies (ADVM) closed the last trading session at $8.67, gaining 18.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $33.86 indicates a 290.5% upside potential.The average comprises seven short-term price targets ranging from a low of $20 to a high of $60, with a standard deviation of $14.05. While the lowest estimate indicates an increase of 130.7% from the curre ...

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retin ...

REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointments of Dr. Rabia Gurses Ozden to the Company's executive leadership team as chief medical officer and Dr. Szilárd Kiss to the Company's Board of Directors. Dr. Ozden has stepped down from the Company's Board of Directors, with Dr. Kiss filling the existing B ...

Adverum Biotechnologies (ADVM) has been on a downward spiral lately with significant selling pressure. After declining 19.7% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting wh ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ___________________________________________________________________ FORM 10-Q ___________________________________________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☒ EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 For the transition period from to Com ...

Exhibit 99.1 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights - Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 - REDWOOD CITY, Calif., May 9, 2024 - Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standar ...

REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET. BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT. H.C. Wainwright 2nd Annual ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Adverum Biotechnologies (ADVM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Adverum Biotechnologies is one of 1051 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adverum Biotechnologies (ADVM) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Adverum Biotechnologies is one of 1054 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank in ...

ADVM股票表现 - ADVM 是一个值得投资者关注的股票[1] - ADVM 所在的医疗 - 生物医学和遗传学领域正在经历强劲的盈利预期修订活动[1] - ADVM 的盈利预期修订活动表现良好，分析师对公司未来前景持乐观态度[3] ADVM盈利预期修订 - 过去一个月，ADVM 的当季盈利预期从每股亏损3.30美元缩小至每股亏损1.30美元，当年盈利预期从每股亏损7.73美元缩小至每股亏损5.18美元[4] - ADVM 获得了Zacks Rank 2 (Buy)的评级，进一步突显了公司的稳健地位[4] ADVM行业地位 - ADVM 所在的行业处于前三分之一的位置，近期盈利预期修订良好，对于寻找这一优秀行业领域的投资者来说，可能是一个非常有趣的选择[5]